Artisan Partners Limited Partnership Sells 2,186,786 Shares of Boston Scientific Corporation $BSX

Artisan Partners Limited Partnership lowered its position in shares of Boston Scientific Corporation (NYSE:BSX) by 46.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,569,376 shares of the medical equipment provider’s stock after selling 2,186,786 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Boston Scientific were worth $244,990,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the company. Claret Asset Management Corp lifted its position in shares of Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its holdings in shares of Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 103 shares during the period. Outfitters Financial LLC raised its holdings in shares of Boston Scientific by 0.5% in the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after purchasing an additional 110 shares during the period. Fayez Sarofim & Co raised its holdings in shares of Boston Scientific by 2.1% in the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock worth $520,000 after purchasing an additional 111 shares during the period. Finally, Natural Investments LLC raised its holdings in shares of Boston Scientific by 2.9% in the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock worth $384,000 after purchasing an additional 112 shares during the period. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of a number of research reports. BTIG Research reaffirmed a “buy” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Tuesday. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Jefferies Financial Group lowered their price target on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Leerink Partners lowered their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a report on Thursday, May 28th. Finally, Truist Financial lowered their price target on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $85.08.

Boston Scientific Trading Up 0.3%

Shares of BSX stock opened at $46.92 on Wednesday. The company’s fifty day simple moving average is $55.74 and its two-hundred day simple moving average is $74.02. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 1 year low of $45.99 and a 1 year high of $109.50. The stock has a market capitalization of $69.74 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 0.89 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has approved a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other news, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 9,800 shares of company stock valued at $554,012 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.